Answers are grounded in this paper and cite their sources.
Class III antiarrhythmic agents and K+ channel openers offer therapeutic promise by modulating cardiac and smooth muscle potassium channels, though specific mechanisms and side effects remain important considerations.
Agents that modulate cardiac and smooth muscle K+ channels have stimulated considerable interest in recent years because of their therapeutic potential in a number of cardiovascular diseases. Foremost among these drugs are the so-called Class III antiarrhythmic agents, which act by prolonging cardiac action potentials, and K+ channel openers, which hyperpolarize and thereby relax smooth muscle cells. Many of the newly developed Class III antiarrhythmic agents probably act by specific block of one subtype of delayed rectifier K+ current, IKr, whereas other agents block more than one type of cardiac K+ current. Much controversy exists over the specific type of K+ channel (or channels) in smooth muscle that are activated by the K+ channel openers. Both groups of K+ channel modulators have great therapeutic promise, but the Class III antiarrhythmic agents may suffer from a side-effect that is directly linked to their specific mechanism of action.
No takes yet. Share an insight, caveat, or question.
Michael C. Sanguinetti (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: